An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs BI 754091 (Primary)
- Indications Bladder cancer; Breast cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Feb 2017 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 23 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 May 2019.
- 19 Dec 2016 Status changed from not yet recruiting to recruiting.